Literature DB >> 22675142

Successful use of allopurinol in a patient on dialysis.

Richard Osborne Day1, Diluk Romesh Wijekoon Kannangara, James M Hayes, Timothy J Furlong.   

Abstract

We report the case of a man with chronic tophaceous gout who had end-stage renal failure secondary to the Alport syndrome. Following a failed kidney transplant, where urate deposition was a suspected contributor, the patient responded positively to consistent allopurinol therapy and regular haemodialysis sessions. Extensive and destructive tophi receded in size remarkably and the almost constant incidence of acute attacks of gout subsided. The patient has recently received a new kidney transplant and his plasma concentrations of urate are controlled well with allopurinol and he no longer experiences acute attacks of gout. While efficacious, adherence is critical for achieving the therapeutic effects of allopurinol even in end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22675142      PMCID: PMC4543064          DOI: 10.1136/bcr.02.2012.5814

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

Review 1.  Editorial: An evaluation of the pathogenesis of gouty kidney.

Authors:  B T Emmerson; P G Row
Journal:  Kidney Int       Date:  1975-08       Impact factor: 10.612

2.  THE USE OF ALLOPURINOL (HPP) TO CONTROL HYPERURICEMIA IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS.

Authors:  C P HAYES; E N METZ; R R ROBINSON; R W RUNDLES
Journal:  Trans Am Soc Artif Intern Organs       Date:  1965

3.  Plasma oxipurinol concentrations during allopurinol therapy.

Authors:  B T Emmerson; R B Gordon; M Cross; D B Thomson
Journal:  Br J Rheumatol       Date:  1987-12

Review 4.  Allopurinol hypersensitivity syndrome: a review.

Authors:  F Arellano; J A Sacristán
Journal:  Ann Pharmacother       Date:  1993-03       Impact factor: 3.154

5.  Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?

Authors:  T V Kot; R O Day; P M Brooks
Journal:  Med J Aust       Date:  1993-08-02       Impact factor: 7.738

6.  Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol.

Authors:  W J Johnson; J D O'Duffy
Journal:  Mayo Clin Proc       Date:  1979-09       Impact factor: 7.616

7.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

8.  Cell-mediated immunity in allopurinol-induced hypersensitivity.

Authors:  G L Braden; M J Warzynski; M Golightly; M Ballow
Journal:  Clin Immunol Immunopathol       Date:  1994-02

9.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

10.  Gout in ambulatory care settings in the United States.

Authors:  Eswar Krishnan; Douglas Lienesch; C Kent Kwoh
Journal:  J Rheumatol       Date:  2008-02-01       Impact factor: 4.666

View more
  2 in total

Review 1.  Managing Gout in the Patient with Renal Impairment.

Authors:  Eliseo Pascual; Francisca Sivera; Mariano Andrés
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

2.  Management of Gout and Hyperuricemia in CKD.

Authors:  Ana Beatriz Vargas-Santos; Tuhina Neogi
Journal:  Am J Kidney Dis       Date:  2017-04-26       Impact factor: 8.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.